BlueCrest Capital Management Ltd lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 31.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,176 shares of the company’s stock after selling 8,005 shares during the period. BlueCrest Capital Management Ltd’s holdings in Neurocrine Biosciences were worth $1,333,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of NBIX. Dimensional Fund Advisors LP raised its position in shares of Neurocrine Biosciences by 6.5% in the second quarter. Dimensional Fund Advisors LP now owns 176,197 shares of the company’s stock worth $8,105,000 after buying an additional 10,782 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after buying an additional 193 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Neurocrine Biosciences by 3.2% in the third quarter. Nationwide Fund Advisors now owns 124,351 shares of the company’s stock worth $7,620,000 after buying an additional 3,800 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in shares of Neurocrine Biosciences in the third quarter worth $286,000. Finally, State Board of Administration of Florida Retirement System raised its position in shares of Neurocrine Biosciences by 0.7% in the third quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after buying an additional 810 shares in the last quarter.
In other news, CEO Kevin Charles Gorman sold 3,750 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $78.89, for a total transaction of $295,837.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director William H. Rastetter sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $90.00, for a total value of $855,000.00. Following the transaction, the director now directly owns 34,250 shares in the company, valued at $3,082,500. The disclosure for this sale can be found here. Insiders have sold 399,589 shares of company stock worth $32,443,795 over the last ninety days. Insiders own 4.80% of the company’s stock.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $90.59 on Tuesday. The company has a market capitalization of $8,090.00, a price-to-earnings ratio of -55.58 and a beta of 0.30. The company has a debt-to-equity ratio of 0.99, a current ratio of 10.20 and a quick ratio of 10.20. Neurocrine Biosciences, Inc. has a 12 month low of $39.21 and a 12 month high of $92.98.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the prior year, the business earned ($0.51) earnings per share. equities analysts forecast that Neurocrine Biosciences, Inc. will post -0.25 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/neurocrine-biosciences-inc-nbix-position-lessened-by-bluecrest-capital-management-ltd.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.